Results 21 to 30 of about 47,575 (225)

Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion

Frontiers in Immunology, 2023
Platelet concentrate (PC) transfusion seeks to provide haemostasis in patients presenting severe central thrombocytopenia or severe bleeding. PCs may induce adverse reactions (AR) that can occasionally be severe (SAR).
Anne-Claire Duchez, Anne-Claire Duchez, Sébastien Fauteux-Daniel, Sébastien Fauteux-Daniel, Caroline Sut, Theo Ebermeyer, Marco Heestermans, Marco Heestermans, Charles-Antoine Arthaud, Charles-Antoine Arthaud, Marie-Ange Eyraud, Marie-Ange Eyraud, Amélie Prier, Amélie Prier, Estelle Audoux, Estelle Audoux, Justine Bertrand-Michel, Justine Bertrand-Michel, Bernard Payrastre, Bernard Payrastre, Olivier Garraud, Eric Boilard, Eric Boilard, Hind Hamzeh-Cognasse, Fabrice Cognasse, Fabrice Cognasse   +25 more
doaj   +1 more source

PrLPAAT4, a Putative Lysophosphatidic Acid Acyltransferase from Paeonia rockii, Plays an Important Role in Seed Fatty Acid Biosynthesis

Molecules, 2017
Lysophosphatidic acid acyltransferases (LPAATs) are essential for the acylation of lysophosphatidic acid (LPA) and the synthesis of phosphatidic acid (PA), a key intermediate in the synthesis of membrane phospholipids and storage lipids. Here, a putative
Qingyu Zhang, Rui Yu, Daoyang Sun, Zhangzhen Bai, Hong Li, Liang Xue, Yanlong Zhang, Lixin Niu   +7 more
doaj   +1 more source

Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal. [PDF]

, 2014
The high mortality of melanoma is caused by rapid spread of cancer cells, which occurs unusually early in tumour evolution. Unlike most solid tumours, thickness rather than cytological markers or differentiation is the best guide to metastatic potential.
A Boucharaba, AD Mackenzie Ross, AJ Houben, AJ Muinonen-Martin, AJ Snider, AL Parrill, AM Algra, Andre Levchenko, Andrew J. Muinonen-Martin, C Carmona-Fontaine, C Scherber, C Zhao, CK Griffith, CM Balch, Colin Lindsay, D Dankort, D Zicha, D Zicha, David A. Knecht, Dorothy C. Bennett, Douwe M. Veltman, E Dona, E Lee, E Sierko, E Theveneau, Elizabeth Smethurst, ET Roussos, F Wach, G Tigyi, G Valentin, G Venkiteswaran, Gabriela Kalna, GL Garcia, J Condeelis, J Condeelis, J Murata, J Sleeman, J Wyckoff, JD Pedelacq, JM Haugh, JP Sleeman, JT Price, K Bandoh, K Jalink, Laura M. Machesky, M Abercrombie, M Gotoh, M Herlyn, M Jongsma, M Zaki, Michael J. O. Wakelam, MJ Payette, N Aaltonen, Olivia Susanto, Owen J. Sansom, P Berens, P Timpson, PN Devreotes, Qifeng Zhang, RA Sturm, Robert H. Insall, Robert Herd, Robert Jones, RR Langley, S Kuriyama, S Toetsch, S Toyozawa, SA Jordan, SH Zigmond, SH Zigmond, SK Hughes-Alford, W Wang, William J. Faller   +72 more
core   +3 more sources

Lysophosphatidic Acid-operated K+ Channels [PDF]

Journal of Biological Chemistry, 2005
Lysophosphatidic acid (LPA) is an abundant cellular lipid with a myriad of biological effects. It plays an important role in both inter- and intracellular signaling. Activation of the LPA1-3 G-protein-coupled receptors explains many of the extracellular effects of LPA, including cell growth, differentiation, survival, and motility.
Jean, Chemin, Amanda, Patel, Fabrice, Duprat, Marc, Zanzouri, Michel, Lazdunski, Eric, Honoré   +5 more
openaire   +3 more sources

A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension.

PLoS ONE, 2014
Autotaxin, also known as ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), is a secreted enzyme that has lysophospholipase D activity, which converts lysophosphatidylcholine to bioactive lysophosphatidic acid. Lysophosphatidic acid activates at
Hiroshi Saga, Akira Ohhata, Akio Hayashi, Makoto Katoh, Tatsuo Maeda, Hirotaka Mizuno, Yuka Takada, Yuka Komichi, Hiroto Ota, Naoya Matsumura, Masami Shibaya, Tetsuya Sugiyama, Shinji Nakade, Katsuya Kishikawa   +13 more
doaj   +1 more source

Structural identification of oxidized acyl-phosphatidylcholines that induce platelet activation [PDF]

, 2005
Oxidation of low-density lipoprotein (LDL) generates proinflammatory and prothrombotic mediators that may play a crucial role in cardiovascular and inflammatory diseases.
Berliner JA, Bittman R, Casals-Stenzal J, Esterbauer H, Fernandez-Ortiz A, Frey B, Goetzl EJ, Holvoet P, Itabe H, Kamido H, Kamido H, Kern H, Kinsella BT, Kitagawa S, O'Flaherty JT, O'Flaherty JT, Rasmussen UB, Sevanian A, Subbanagounder G, Tanaka T, Trip MD, Volf I, Watson AD, Weidtmann A   +23 more
core   +1 more source

Rho/ROCK acts downstream of lysophosphatidic acid receptor 1 in modulating P2X receptor-mediated bone cancer pain in rats

Molecular Pain, 2016
Background Lysophosphatidic acid receptor 1 and Rho/ROCK signaling is implicated in bone cancer pain development. However, it remains unknown whether the two signaling pathways function together in P2X 3 receptor-mediated bone cancer pain.
Jing-xiang Wu MD, Xiao-min Yuan MMed, Qiong Wang MMed, Wang Wei MM (cand), Mei-ying Xu MBBS   +4 more
doaj   +1 more source

Exosomes promote pre-metastatic niche formation in ovarian cancer. [PDF]

, 2019
Ovarian cancer is one of the most common gynecological malignancies. Upon initial diagnosis, the majority of patients present with widespread metastatic growth within the peritoneal cavity. This metastatic growth occurs in stages, with the formation of a
Dean, Dylan C, Duan, Zhenfeng, Feng, Wenlong, Hornicek, Francis J, Shi, Huirong   +4 more
core   +2 more sources

Lysophosphatidic acid synthesis and release [PDF]

Prostaglandins & Other Lipid Mediators, 2001
Lysophosphatidic acid (LPA) is a bioactive phospholipid controlling numerous cellular responses through the activation of specific G-protein coupled transmembrane receptors. LPA is present in several biological fluids (serum, plasma, aqueous humor) and can be secreted by several cell types (platelets, fibroblasts, adipocytes, cancer cells).
Pagès, Céline, Simon, Marie-Françoise, Valet, Philippe, Saulnier-Blache, Jean Sébastien   +3 more
openaire   +3 more sources

Lysophosphatidic acid in atherosclerotic diseases [PDF]

British Journal of Pharmacology, 2012
Lysophosphatidic acid (LPA) is a potent bioactive phospholipid. As many other biological active lipids, LPA is an autacoid: it is formed locally on demand, and it acts locally near its site of synthesis. LPA has a plethora of biological activities on blood cells (platelets, monocytes) and cells of the vessel wall (endothelial cells, smooth muscle cells,
Andreas, Schober, Wolfgang, Siess
openaire   +2 more sources